IP Library › Patent Application 17469625
Patent Application
App. No. 17/469,625

METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/469,625
Abstract

The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring, the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual.

Claims (118)

1 . A method of reducing the level of autoantibody or alloantibody titers in an individual in need thereof, the method comprising administering to the individual an effective amount of an antibody that specifically binds complement component 1s (C1s), wherein the antibody comprises complementarity determining regions (CDRs) of:

i) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7;

ii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:94 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93;

iii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:100;

iv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:103 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:102;

v) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:105 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:104;

vi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:107 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:106;

vii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:109 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:108;

viii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:111 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:110;

ix) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:113 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:112;

x) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:115 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:114;

xi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:117 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:116;

xii) an antibody light chain variable region the comprising amino acid sequence set forth in SEQ ID NO:119 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:118;

xiii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:121 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:120;

xiv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:123 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:122; or

xv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:125 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:124.

2 . The method of claim 1 , comprising monitoring efficacy of said administering comprising detecting a level of autoantibody or alloantibody in a biological sample obtained from the individual.

3 . The method of claim 2 , comprising adjusting the dose of the antibody based on the detected level.

4 . The method of claim 1 , wherein the individual is a human.

5 . The method of claim 1 , wherein the antibody is a humanized antibody.

6 .- 9 . (canceled)

10 . A method of reducing B-cell proliferation or B-cell activation in an individual in need thereof, the method comprising administering to the individual an effective amount of an antibody that specifically binds complement component 1s (C1s), wherein the antibody comprises complementarity determining regions (CDRs) of:

i) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7;

ii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:94 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93;

iii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:100;

iv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:103 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:102;

v) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:105 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:104;

vi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:107 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:106;

vii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:109 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:108;

viii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:111 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:110;

ix) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:113 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:112;

x) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:115 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:114;

xi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:117 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:116;

xii) an antibody light chain variable region the comprising amino acid sequence set forth in SEQ ID NO:119 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:118;

xiii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:121 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:120;

xiv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:123 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:122; or

xv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:125 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:124.

11 . The method of claim 10 , comprising monitoring efficacy of said administering comprising detecting a level of B-cell proliferation or B-cell activation in a biological sample obtained from the individual.

12 . The method of claim 11 , comprising adjusting the dose of the antibody based on the detected level.

13 . The method of claim 10 , wherein the individual is a human.

14 . The method of claim 10 , wherein the antibody is a humanized antibody.

15 .- 27 . (canceled)

28 . The method of claim 1 , wherein the antibody is administered intravenously, subcutaneously, or intramuscularly.

29 . The method of claim 1 , wherein the antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence GFNIKDDYIHWV (SEQ ID NO:9); the amino acid sequence IDPADGHTKY (SEQ ID NO: 10); and the amino acid sequence ARYGYGREVFDY (SEQ ID NO: 11); and a light chain variable region comprising the amino acid sequence QSVDYDGDSYMN (SEQ ID NO: 12); the amino acid sequence DASNLESGIP (SEQ ID NO: 13); and the amino acid sequence QQSNEDPWT (SEQ ID NO: 14); or

b) a heavy chain variable region comprising the amino acid sequence NYAMS (SEQ ID NO:95), the amino acid sequence TISSGGSHTYYLDSVKG (SEQ ID NO:96), and the amino acid sequence LFTGYAMDY (SEQ ID NO:97); and a light chain variable region comprising the amino acid sequence TASSSVSSSYLH (SEQ ID NO:98), the amino acid sequence STSNLAS (SEQ ID NO:99), and the amino acid sequence HQYYRLPPIT (SEQ ID NO:92).

30 . The method of claim 10 , wherein the antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence GFNIKDDYIHWV (SEQ ID NO:9); the amino acid sequence IDPADGHTKY (SEQ ID NO: 10); and the amino acid sequence ARYGYGREVFDY (SEQ ID NO: 11); and a light chain variable region comprising the amino acid sequence QSVDYDGDSYMN (SEQ ID NO: 12); the amino acid sequence DASNLESGIP (SEQ ID NO: 13); and the amino acid sequence QQSNEDPWT (SEQ ID NO: 14); or

b) a heavy chain variable region comprising the amino acid sequence NYAMS (SEQ ID NO:95); the amino acid sequence TISSGGSHTYYLDSVKG (SEQ ID NO:96); and the amino acid sequence LFTGYAMDY (SEQ ID NO:97); and a light chain variable region comprising the amino acid sequence TASSSVSSSYLH (SEQ ID NO:98); the amino acid sequence STSNLAS (SEQ ID NO:99); and the amino acid sequence HQYYRLPPIT (SEQ ID NO:92).

31 . A method of monitoring the efficacy of a treatment method comprising administering an antibody that specifically binds complement component 1s (C1s) to an individual, the monitoring method comprising detecting a level of autoantibody or alloantibody in a biological sample obtained from the individual, wherein a decrease in the level of autoantibody or alloantibody, compared to a pre-treatment level, indicates efficacy of the treatment, and wherein the antibody comprises complementarity determining regions (CDRs) of:

i) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7;

ii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:94 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93;

iii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:100;

iv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:103 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:102;

v) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:105 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:104;

vi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:107 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:106;

vii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:109 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:108;

viii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:111 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:110;

ix) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:113 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:112;

x) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:115 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:114;

xi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:117 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:116;

xii) an antibody light chain variable region the comprising amino acid sequence set forth in SEQ ID NO:119 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:118;

xiii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:121 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:120;

xiv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:123 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:122; or

xv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:125 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:124.

32 .- 35 (canceled)

36 . The method of claim 10 , wherein the antibody is administered intravenously, subcutaneously, or intramuscularly.

37 . The method of claim 1 , wherein the antibody comprises:

i) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7;

ii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:94 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93;

iii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:100;

iv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:103 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:102;

v) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:105 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:104;

vi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:107 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:106;

vii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:109 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:108;

viii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:111 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:110;

ix) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:113 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:112;

x) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:115 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:114;

xi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:117 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:116;

xii) an antibody light chain variable region the comprising amino acid sequence set forth in SEQ ID NO:119 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:118;

xiii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:121 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:120;

xiv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:123 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:122; or xv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:125 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:124.

38 . The method of claim 10 , wherein the antibody comprises:

i) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7;

ii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:94 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93;

iii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:100;

iv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:103 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:102;

v) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:105 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:104;

vi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:107 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:106;

vii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:109 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:108;

viii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:111 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:110;

ix) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:113 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:112;

x) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:115 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:114;

xi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:117 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:116;

xii) an antibody light chain variable region the comprising amino acid sequence set forth in SEQ ID NO:119 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:118;

xiii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:121 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:120;

xiv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:123 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:122; or

xv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:125 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:124.

39 . The method of claim 31 , wherein the antibody comprises:

i) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7;

ii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:94 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:93;

iii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:100;

iv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:103 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:102;

v) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:105 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:104;

vi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:107 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:106;

vii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:109 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:108;

viii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:111 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:110;

ix) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:113 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:112;

x) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:115 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:114;

xi) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:117 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:116;

xii) an antibody light chain variable region the comprising amino acid sequence set forth in SEQ ID NO:119 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:118;

xiii) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:121 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:120;

xiv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:123 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:122; or

xv) an antibody light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:125 and an antibody heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:124.

40 . The method of claim 31 , wherein the antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence GFNIKDDYIHWV (SEQ ID NO:9); the amino acid sequence IDPADGHTKY (SEQ ID NO: 10); and the amino acid sequence ARYGYGREVFDY (SEQ ID NO: 11); and a light chain variable region comprising the amino acid sequence QSVDYDGDSYMN (SEQ ID NO: 12); the amino acid sequence DASNLESGIP (SEQ ID NO: 13); and the amino acid sequence QQSNEDPWT (SEQ ID NO: 14); or

b) a heavy chain variable region comprising the amino acid sequence NYAMS (SEQ ID NO:95), the amino acid sequence TISSGGSHTYYLDSVKG (SEQ ID NO:96), and the amino acid sequence LFTGYAMDY (SEQ ID NO:97); and a light chain variable region comprising the amino acid sequence TASSSVSSSYLH (SEQ ID NO:98), the amino acid sequence STSNLAS (SEQ ID NO:99), and the amino acid sequence HQYYRLPPIT (SEQ ID NO:92).

41 . The method of claim 31 , wherein the antibody is administered intravenously, subcutaneously, or intramuscularly.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2021
From: PARRY, GRAHAM; NIKITIN, PAVEL A.; PANICKER, SANDIP
To: BIOVERATIV USA INC.
Reel/Frame 058197/0040 →